Entrada Therapeutics (TRDA) Operating Margin: 2023-2025
Historic Operating Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Sep 2025 value amounting to -2,915.18%.
- Entrada Therapeutics' Operating Margin fell 280451.00% to -2,915.18% in Q3 2025 from the same period last year, while for Sep 2025 it was -197.59%, marking a year-over-year decrease of 22444.00%. This contributed to the annual value of 22.30% for FY2024, which is 2475.00% up from last year.
- As of Q3 2025, Entrada Therapeutics' Operating Margin stood at -2,915.18%, which was down 21.34% from -2,402.51% recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' Operating Margin registered a high of 56.42% during Q2 2024, and its lowest value of -2,915.18% during Q3 2025.
- Over the past 3 years, Entrada Therapeutics' median Operating Margin value was -22.88% (recorded in 2023), while the average stood at -502.43%.
- As far as peak fluctuations go, Entrada Therapeutics' Operating Margin spiked by 14,612bps in 2024, and later tumbled by 280,451bps in 2025.
- Over the past 3 years, Entrada Therapeutics' Operating Margin (Quarterly) stood at 11.72% in 2023, then crashed by 2,741bps to -15.69% in 2024, then plummeted by 280,451bps to -2,915.18% in 2025.
- Its Operating Margin stands at -2,915.18% for Q3 2025, versus -2,402.51% for Q2 2025 and -105.99% for Q1 2025.